Literature DB >> 34217109

Promising therapeutic approaches in pulmonary arterial hypertension.

Md Khadem Ali1, Kenzo Ichimura1, Edda Spiekerkoetter2.   

Abstract

Pulmonary arterial hypertension (PAH) is a debilitating multifactorial disease characterized by progressive pulmonary vascular remodeling, elevated pulmonary arterial pressure, and pulmonary vascular resistance, resulting in right ventricular failure and subsequent death. Current available therapies do not reverse the disease, resulting in a persistent high morbidity and mortality. Thus, there is an urgent unmet medical need for novel effective therapies to better treat patients with PAH. Over the past few years, enthusiastic attempts have been made to identify novel effective therapies that address the essential roots of PAH with targeting key signaling pathways in both preclinical models and patients with PAH. This review aims to discuss the most emerging and promising therapeutic interventions in PAH pathogenesis.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2021        PMID: 34217109     DOI: 10.1016/j.coph.2021.05.003

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  3 in total

Review 1.  NR4A3: A Key Nuclear Receptor in Vascular Biology, Cardiovascular Remodeling, and Beyond.

Authors:  José Martínez-González; Laia Cañes; Judith Alonso; Carme Ballester-Servera; Antonio Rodríguez-Sinovas; Irene Corrales; Cristina Rodríguez
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

Review 2.  Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis.

Authors:  Pengwei Wang; Jiaxin Deng; Quanying Zhang; Hongyan Feng; Yongheng Zhang; Yizhong Lu; Lizhu Han; Pengfei Yang; Zhijian Deng
Journal:  Front Pharmacol       Date:  2022-02-09       Impact factor: 5.810

3.  Editorial overview: Respiratory: Pulmonary pharmacology-The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives.

Authors:  Mario Cazzola; Maria Gabriella Matera; Luigino Calzetta; Paola Rogliani
Journal:  Curr Opin Pharmacol       Date:  2021-08-02       Impact factor: 5.547

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.